Long-Term Hyperbaric Oxygen in Chronic Progressive Multiple Sclerosis: A Placebo-Controlled Double-Blind Randomized Study with Evoked Potential Evaluation
The immunosuppressive action of hyperbaric oxygen (HBOX) has been proved by experimental studies in allergic encephalomyelitis  and other pathologies. Since 1970, clinical studies, most of them uncontrolled and nonblind, have been set up to evaluate the possible efficacy of HBOX in patients with multiple sclerosis (MS). The results have been controversial: some trials reported a positive action of HBOX  while others have not shown any clinical improvement .
KeywordsMultiple Sclerosis Hyperbaric Oxygen Sphincteric Function Cerebellar Function Multiple Sclerosis Group
Unable to display preview. Download preview PDF.
- 2.Fischer BH, Marks M, Reich F (1983) Hyperbaric oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Engl J Med 308:181–186Google Scholar
- 3.Barnes MP, Bates D, Cartlidge NEF, French JM, Shaw DA (1985) Hyperbaric oxygen and multiple sclerosis: short-term results of a placebo-controlled, double-blind trial. Lancet i: 297–300Google Scholar
- 5.Kurtzke JF (1984) The evaluation of disability in mutliple sclerosis: In: Scheinberg L, Raine CS (eds) M.S.: experimental and clinical aspects. Ann NY Acad Sci 436Google Scholar